SLA Genetic Polymorphism and Large Scale Gene Expression Profiling of Cloned SNU Miniature Pigs Derived from Same Cell Line

2013 ◽  
Vol 37 (1) ◽  
pp. 1-8
Author(s):  
Su-Cheong Yeom ◽  
◽  
Ok Jae Koo ◽  
Chung-Gyu Park ◽  
Byeong-Chun Lee ◽  
...  
Endocrine ◽  
2008 ◽  
Vol 33 (1) ◽  
pp. 62-76 ◽  
Author(s):  
Katharina H. Ruebel ◽  
Alexey A. Leontovich ◽  
Yoshinori Tanizaki ◽  
Long Jin ◽  
Gail A. Stilling ◽  
...  

Viruses ◽  
2019 ◽  
Vol 12 (1) ◽  
pp. 36
Author(s):  
Christopher Dächert ◽  
Evgeny Gladilin ◽  
Marco Binder

Chronic Hepatitis C virus (HCV) infection still constitutes a major global health problem with almost half a million deaths per year. To date, the human hepatoma cell line Huh7 and its derivatives is the only cell line that robustly replicates HCV. However, even different subclones and passages of this single cell line exhibit tremendous differences in HCV replication efficiency. By comparative gene expression profiling using a multi-pronged correlation analysis across eight different Huh7 variants, we identified 34 candidate host factors possibly affecting HCV permissiveness. For seven of the candidates, we could show by knock-down studies their implication in HCV replication. Notably, for at least four of them, we furthermore found that overexpression boosted HCV replication in lowly permissive Huh7 cells, most prominently for the histone-binding transcriptional repressor THAP7 and the nuclear receptor NR0B2. For NR0B2, our results suggest a finely balanced expression optimum reached in highly permissive Huh7 cells, with even higher levels leading to a nearly complete breakdown of HCV replication, likely due to a dysregulation of bile acid and cholesterol metabolism. Our unbiased expression-profiling approach, hence, led to the identification of four host cellular genes that contribute to HCV permissiveness in Huh7 cells. These findings add to an improved understanding of the molecular underpinnings of the strict host cell tropism of HCV.


2006 ◽  
Vol 54 (11) ◽  
pp. 3533-3544 ◽  
Author(s):  
Thomas Aigner ◽  
Katrin Fundel ◽  
Joachim Saas ◽  
Pia M. Gebhard ◽  
Jochen Haag ◽  
...  

Author(s):  
Marja Steenman ◽  
Guillaume Lamirault ◽  
Nolwenn Le Meur ◽  
Jean J. Léger

AbstractGene expression profiling studies in human diseases have allowed better understanding of pathophysiological processes. In addition, they may lead to the development of new clinical tools to improve diagnosis and prognosis of patients. Most of these studies have been successfully performed for human cancers. Inspired by these results, researchers in the cardiovascular field have also started using large-scale transcriptional analysis to better understand and classify human cardiovascular disease. Here we provide an overview of the literature revealing new cardiac disease markers and encouraging results for further development of the expression profiling strategy for future clinical applications in cardiology.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 5050-5050
Author(s):  
Asher Alban Chanan-Khan ◽  
Noreen Ersing ◽  
Paula Pera ◽  
Ralph Bernaki ◽  
Lionel Coignet ◽  
...  

Abstract Introduction: Bortezomib (B) is the first in class proteasome inhibitor that received FDA approval for the treatment of MM patients with relapsed or refractory disease. Despite impressive clinical activity all patients develop resistance to B. The underlying mechanism of resistance to B remains undetermined. Mechanisms to overcome B resistance or development of new therapeutic agent(s) with activity in context of B resistance are limited due to unavailability of established preclinical B resistant MM models. To overcome this challenge we developed a B resistant HMCL. Methods: we chronically exposed the OPM-2 HMCL to sub-lethal doses of B. Surviving cells were harvested, re-cultured and dose of B incrementally increased over prolong period of time. The resulting resistant cells were further characterized using array Comparative Genomic Hybridization (aCGH), spectral karyotyping (SKY) and gene expression profiling. Results: After several passages we were able to induce B resistance in this HMCL. Final clone (OPM-2BR) demonstrate resistance to 2 × IC50 dose of B. While SKY and aCGH analysis demonstrated significant differences when compared with parent OPM-2WT (wild type) HMCL, gene expression profiling of the resistant and parental lines demonstrated significant upregulation in the expression of a number of ATP-binding cassette transporters. For example, the breast cancer resistance protein (ABCG2) is upregulated 4-fold in the resistant cell line compared to the parental cell line. This data suggests that drug efflux mediated by drug transporters represents one potential mechanism of resistance to B. Conclusion: Chronic in vitro B exposure results in induced resistance in HMCL-OPM-2BR. Resistant cell line demonstrates cytogenetic variability when compared to the parent cell line. Induction of resistance is stable and provides an important preclinical tool to investigate mechanism(s) of B resistance as well as new drug development for B resistant myeloma patients. Detailed analysis of this cell lines including therapeutic interventions investigating resistance reversal will be presented at the meeting.


Toxicology ◽  
2013 ◽  
Vol 303 ◽  
pp. 94-98 ◽  
Author(s):  
Yu Ri An ◽  
Seung Jun Kim ◽  
Moon-Ju Oh ◽  
Hyun-Mi Kim ◽  
Il-Seob Shim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document